From: Reduced expression of SMAD4 in gliomas correlates with progression and survival of patients
Clinicopathological features | No. of cases | SMAD4 (n) | P | |||
---|---|---|---|---|---|---|
 |  | - | + | ++ | +++ |  |
WHO grade | Â | 114 | 60 | 51 | 27 | Â |
I | 53 | 12 | 16 | 13 | 12 | 0.008 |
II | 60 | 17 | 21 | 15 | 7 | Â |
III | 62 | 34 | 12 | 11 | 5 | Â |
IV | 77 | 51 | 11 | 12 | 3 | Â |
Age | Â | Â | Â | Â | Â | Â |
<55 | 152 | 65 | 39 | 31 | 17 | NS |
≥55 | 100 | 49 | 21 | 20 | 10 |  |
Gender | Â | Â | Â | Â | Â | Â |
Male | 138 | 57 | 36 | 30 | 15 | NS |
Female | 114 | 57 | 24 | 21 | 12 | Â |
KPS | Â | Â | Â | Â | Â | Â |
<80 | 135 | 81 | 25 | 21 | 8 | <0.001 |
≥80 | 117 | 33 | 35 | 30 | 19 |  |